We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

The Dream of Biologics in Uveitis

Annabelle A. Okada, MD
Arch Ophthalmol. 2010;128(5):632-635. doi:10.1001/archophthalmol.2010.47.
Text Size: A A A
Published online


Biologic therapy may be broadly defined as treatment using an agonist or an antagonist to specifically enhance or suppress the level of a naturally occurring protein molecule to manipulate a disease state. Agonists used in biologic therapy include a variety of cytokines and growth factors. Antagonists include monoclonal antibodies and other agents capable of binding soluble and/or cell membrane–bound proteins.

The era of biologic therapy in medicine really began more than 2 decades ago. Using recombinant DNA technology to produce human proteins, the cytokine interferon alfa was made commercially available in the United States in 1981. Interferon alfa is now approved for use in diseases such as chronic hepatitis C and hairy cell leukemia and is also used off label in a myriad of conditions. In ophthalmology, interferon alfa has been shown to be effective in patients with ocular Behçet disease16 and has been included as a second-line agent for the treatment of this disease in European League Against Rheumatism 2008 guidelines.7

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

7 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
The Biological Agent